> 首页 > 产品 > 一抗 > 基因重组 > Anti-GFRAL Reference Antibody (NGM120)

Anti-GFRAL Reference Antibody (NGM120)

Recombinant Antibody

Anti-GFRAL Reference Antibody (NGM120) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-GFRAL Reference Antibody (NGM120) is 100%, determined by SEC-HPLC.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q6UXV0
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	44518 Da

Additional Information
Target/Specificity	GFRAL
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	GFRAL {ECO:0000303\|PubMed:28846097, ECO:0000312\|HGNC:HGNC:32789}
Function	Brainstem-restricted receptor for GDF15 hormone, which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses (PubMed:28846097, PubMed:28846098, PubMed:28846099, PubMed:28953886, PubMed:36630958). The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future (PubMed:28846097, PubMed:28846098, PubMed:28846099, PubMed:28953886, PubMed:36630958). The GDF15-GFRAL aversive response is triggered by stresses, such as anticancer drugs (camptothecin or cisplatin), cancers or drugs such as metformin (PubMed:32661391). Upon interaction with its ligand, GDF15, mediates the GDF15-induced autophosphorylation and activation of the RET tyrosine kinase receptor, leading to activation of MAPK- and AKT- signaling pathways (PubMed:31535977, PubMed:32661391). Ligand- binding activates GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem (By similarity). The GDF15-GFRAL signal induces expression of genes involved in metabolism, such as lipid metabolism in adipose tissues (PubMed:32661391).
Cellular Location	Cell membrane; Single-pass membrane protein; Extracellular side
Tissue Location	Expressed in the brainstem, restricted to cells in the area postrema and the immediately adjacent region of the nucleus tractus solitarius (at protein level) (PubMed:28846097, PubMed:28846098). Detected at low levels in testis and adipose tissue (PubMed:28846097).